Can I Use Insurance for Psychedelic Services or Treatment?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Adults exploring psychedelic services or treatment who want to understand current insurance coverage — what is covered, what is not, what the limited exceptions are, and where this is likely to go.

The short answer

Standard health insurance does not cover psilocybin services in Oregon or Colorado, MDMA-assisted therapy, or most ketamine infusions for psychiatric conditions. The one meaningful exception in the psychedelic-adjacent space is esketamine (Spravato), the FDA-approved nasal spray version of ketamine for treatment-resistant depression, which is covered by most major commercial insurers, Medicare Part B, and many Medicaid plans. A handful of employer benefit plans now offer psilocybin coverage through a specialized benefits administrator as a medical tourism benefit. Everything else in this space is out of pocket.

Oregon and Colorado psilocybin services: no standard insurance coverage

Oregon’s licensed psilocybin services program and Colorado’s licensed healing center program operate entirely outside the standard insurance system. Neither program has created a billing or reimbursement pathway with health insurers.

The reasons are structural. Psilocybin remains a Schedule I controlled substance under federal law. Insurers — including Medicare, Medicaid, and private plans — do not cover treatments involving federally illegal Schedule I substances. Even at the state level where psilocybin services are legal, the services are designed as a wellness model, not a medical treatment. Oregon’s Informed Consent document explicitly states that psilocybin services are not a medical or clinical treatment. Oregon service centers are not health care facilities. Facilitators are not medical providers. These design choices, which reflect the Oregon program’s legal and political architecture, also prevent the program from fitting into standard medical billing structures.

Typical costs in Oregon run $1,000 to $3,000 or more for a complete session cycle including preparation and administration. Colorado’s program has similar cost ranges. All costs are paid out of pocket.

The Enthea exception

As of 2025, Enthea — described as the first and only licensed benefits administrator offering employer-sponsored coverage for psychedelic-assisted care — expanded its offerings to include psilocybin services in Oregon. Enthea works through employer and union benefit plans, not individual insurance plans, to cover costs for employees to travel to Oregon for licensed psilocybin sessions.

This is not standard health insurance coverage. It is an employer benefit — similar to a medical travel benefit — that employers and unions opt into by contracting with Enthea. Whether this benefit is available to any given individual depends on whether their employer has adopted an Enthea plan. As of early 2026, this is a narrow channel. Bendable Therapy in Bend, Oregon announced in April 2025 that it had become the first service center in the state to accept coverage through Enthea.

If you are interested in whether your employer’s benefits include psilocybin coverage, the question to ask your HR or benefits administrator is whether the plan includes psychedelic-assisted therapy or whether your plan works with Enthea or a similar administrator.

MDMA-assisted therapy: not covered

MDMA remains Schedule I with no approved state program and no pathway to insurance coverage. The FDA rejected Lykos Therapeutics’ application in August 2024. Until and unless a synthetic MDMA product receives FDA approval and enters the commercial market, insurance coverage is not available and clinical access is limited to authorized research trials.

Ketamine: a split picture

Ketamine occupies a different legal category from psilocybin and MDMA. It is a Schedule III controlled substance, FDA-approved since the 1970s as an anesthetic, and widely used off-label by licensed physicians for psychiatric conditions. This creates coverage rules that differ meaningfully from the classic psychedelics.

Esketamine (Spravato): broadly covered

Esketamine, sold as Spravato, is a nasal spray version of ketamine’s S-enantiomer that received FDA approval in 2019 for treatment-resistant depression in adults, and for major depressive disorder with suicidal thoughts or actions. Because it is FDA-approved, Spravato fits into standard insurance billing.

Most major commercial insurers — including Aetna, Cigna, Anthem/Blue Cross Blue Shield, and United Healthcare — cover Spravato for treatment-resistant depression. Medicare Part B covers Spravato when administered at a REMS-certified facility, after the Part B deductible ($257 in 2025), covering 80% of costs with the patient responsible for 20%. Many state Medicaid plans also cover Spravato.

Coverage comes with conditions. Prior authorization is typically required. Most plans require documentation that the patient has tried and not responded to at least two antidepressants. Treatment must occur at a clinic enrolled in the FDA’s Spravato Risk Evaluation and Mitigation Strategy (REMS) program, which mandates on-site administration and monitoring. Spravato cannot be taken home.

IV ketamine infusions: almost never covered

Standard ketamine — administered as an IV infusion for psychiatric conditions — is an off-label use of a drug FDA-approved as an anesthetic. Off-label prescribing is legal, common, and clinically supported. But insurers, including Medicare, generally do not cover off-label uses of drugs that lack the clinical-endorsement framework required for coverage. Most major commercial plans, Medicare, and most Medicaid programs do not cover IV ketamine for depression, PTSD, or other psychiatric conditions. Typical cost for a course of six IV ketamine infusions runs $2,400 to $6,400, all out of pocket.

Some exceptions exist: a small number of Kaiser Permanente plans cover IV ketamine under specific clinical conditions. The VA covers IV ketamine at select VA Medical Centers for eligible veterans with treatment-resistant depression, under strict protocols. These are exceptions, not the rule.

HSA (Health Savings Account) and FSA (Flexible Spending Account) funds can generally be used for medically necessary mental health treatment, and some ketamine infusions may qualify depending on how the clinic codes and documents the treatment. This does not make the infusion covered by insurance — it means you can pay with pre-tax dollars.

What may change and when

The AMA has created Category III CPT tracking codes for psychedelic-assisted therapy services to collect utilization data. These codes are not yet reimbursable — they are placeholders in the billing system to accumulate data that could eventually support coverage decisions. The AMA evaluates new service codes annually, and if utilization data accumulates and FDA approvals occur, these codes could be upgraded to Category I status, which would allow standard billing and reimbursement.

COMPASS Pathways’ synthetic psilocybin product (COMP360) met its primary endpoint in a Phase 3 trial for treatment-resistant depression in June 2025. A second Phase 3 trial is expected to report in 2026, with a potential NDA submission in late 2026 or early 2027. If that product receives FDA approval, it would be a prescription drug — a different product from the natural psilocybin used in Oregon and Colorado — and insurers would evaluate it for coverage under the same framework as other approved drugs. FDA approval of a synthetic psilocybin product would not automatically make Oregon’s or Colorado’s psilocybin services insurable.

Practical considerations for people who cannot afford out-of-pocket costs

Clinical trials for psilocybin, MDMA, and ketamine are generally free to participants. For people who cannot afford Oregon or Colorado session costs, clinical trial participation is currently the primary path to no-cost supervised psychedelic access. Clinical trials vs. legal access programs: what’s the difference? covers how trials work and what participation involves.

Some Oregon service centers have begun offering sliding-scale pricing or reduced-cost sessions. Asking directly about reduced-cost options is worth doing. The OHA does not regulate pricing, so variation between providers is significant.

Spravato, for those with qualifying diagnoses, can substantially reduce out-of-pocket costs relative to IV ketamine. The Janssen (manufacturer) patient assistance program provides Spravato at no cost for eligible patients who meet income and insurance criteria.

Cost, access, and legal alternatives when state program services are out of reach addresses the full range of access options for people facing financial barriers.

When public information may be enough

If your question is whether insurance covers psilocybin services or other psychedelic treatments, this article covers the current state of coverage. For what out-of-pocket costs typically look like for Oregon and Colorado sessions, Oregon psilocybin services explained for clients and Colorado natural medicine explained for participants include cost information. For clinical trials as a no-cost alternative, Clinical trials vs. legal access programs: what’s the difference? covers the structure and requirements. For the full picture of access options when cost is a barrier, Cost, access, and legal alternatives when state program services are out of reach addresses that directly.

When you should speak with a lawyer

You should speak with a lawyer if:

You are a healthcare provider interested in billing for psychedelic-adjacent services and want to understand compliant coding and documentation practices
You believe an insurer wrongfully denied coverage for a service you think should be covered and want to understand your appeal rights
You are an employer or benefits administrator interested in structuring a psychedelic-therapy benefit and want to understand the legal and compliance considerations

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.